Reform the FDA citizen petition process to prevent it from being misused to delay approval of generic drugs and biosimilars.

Susan M. Collins · Maine · Republican

policy impact 0.70 specificity 0.82 extraction confidence 93%

Contest this claim

Occurrences

Senator Collins: I want to ask you about another reform that Senator Shaheen and I have been pushing, and it would reform the FDA citizen petition process.

Collins says she and Senator Shaheen are pushing a reform of the FDA citizen petition process to stop anti-competitive delays to generic and biosimilar approvals.

At HELP Hearing on Prescription Drug Aff... | U.S. Senator Susan Collins
primary · official_post · model gpt-5.4-mini

Evidence

Full Committee Hearing titled "From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation" was held on Thursday, February 26, 2026.

Recent Senate attention to FDA process barriers, but no direct evidence in the lookback window that Collins personally reformed the citizen-petition process.

unresolved same_term

From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation | Senate Committee On Aging
secondary · model gpt-5.4-mini · confidence 72%

Contest this evidence item

Axios reported that Sen. Susan Collins introduced a bill that would require biologic drug patents to be included on a list already maintained by the FDA.

Concrete later-term legislative action on a related drug-competition barrier, but it addressed patent listing rather than the FDA citizen-petition process itself.

partial later_term A for effort

Senate makes bipartisan strides toward drug patents
secondary · model gpt-5.4-mini · confidence 67%

Contest this evidence item

Assessments

partial later_term

The available evidence does not show that Susan Collins achieved a reform of the FDA citizen-petition process itself. The 2026 Senate hearing reflects general attention to FDA barriers but not a delivered change by Collins on this specific mechanism. The 2019 bill on biologic patent listing addressed a related obstacle to generic and biosimilar competition, so it supports some credit for working on adjacent drug-approval delays, but it does not amount to fulfillment of the promised citizen-petition reform. Because the observed action is related but not the promised reform, partial credit fits better than full delivery or a documented serious failed attempt on the exact promise.

provider codex_cli · model gpt-5.4 · confidence 79%